Show results for
Refine by
Vaccinator Equipment Supplied In Sweden
27 equipment items found
Manufactured by:Scandinavian Biopharma based inSolna, SWEDEN
diTekiBooster is indicated for booster vaccination against diphtheria, tetanus and pertussis of individuals from the age of four years ...
Manufactured by:Scandinavian Biopharma based inSolna, SWEDEN
diTekiBooster is indicated for booster vaccination against diphtheria, tetanus and pertussis of individuals from the age of four years ...
Manufactured by:Novavax based inGaithersburg, MARYLAND (USA)
Older adults (aged 60 years and older) are at increased risk for RSV disease due in part to immunosenescence, the age-related decline in the human immune system. RSV infection can also lead to exacerbation of underlying comorbidities such as chronic obstructive pulmonary disease, asthma, and congestive heart failure. In the United States alone, a reported RSV incidence rate of 5.5% in older ...
Manufactured by:Scandinavian Biopharma based inSolna, SWEDEN
Vivotif is indicated for active oral immunisation against typhoid fever, caused by Salmonella enterica serovar Typhi, (S. Typhi), in adults and children aged five years and ...
Manufactured by:Scandinavian Biopharma based inSolna, SWEDEN
diTeBooster is a vaccine that provides protection against diphtheria and tetanus. This booster vaccine is used to vaccinate children (5 years or older) and adults who have already received primary vaccination against diphtheria and ...
Manufactured by:Novavax based inGaithersburg, MARYLAND (USA)
We have developed an EBOV glycoprotein vaccine candidate (Ebola GP vaccine) expressed in insect cells, using our core recombinant baculovirus technology. In 5 separate studies, carried out in collaboration with the National Institute of Allergy and Infectious Diseases, active immunization with the Ebola GP vaccine was shown to be highly ...
Manufactured by:2A Pharma ApS based inAalborg Øst, DENMARK
The global market for prophylactic HPV vaccines is likely to grow rapidly as more and more countries expand national vaccination programs to include HPV vaccinations not only for girls but also for boys. In addition, it is now estimated that 60-70% of oropharyngeal cancers are caused by HPV virus infections, opening up a discussion on HPV ...
Manufactured by:Scandinavian Biopharma based inSolna, SWEDEN
BCG Vaccine AJVaccines contains bacteria of the type Mycobacterium bovis BCG and is used for protection against tuberculosis ...
Manufactured by:2A Pharma ApS based inAalborg Øst, DENMARK
2A Pharma’s anti-autoimmune vaccine candidate has potential in a number of indications. The vaccine is currently being tested in a vitiligo model in collaboration with different ...
Manufactured by:Scandinavian Biopharma based inSolna, SWEDEN
BCG Vaccine AJVaccines contains bacteria of the type Mycobacterium bovis BCG and is used for protection against tuberculosis ...
Manufactured by:Novavax based inGaithersburg, MARYLAND (USA)
ResVax is our aluminum-adjuvanted RSV F vaccine for infants via maternal immunization. RSV is the most common cause of lower respiratory tract infections (LRTI) and the leading viral cause of severe lower respiratory tract disease in infants and young children worldwide. In the United States, RSV is the leading cause of hospitalization of infants and, globally, is second only to ...
Manufactured by:Novavax based inGaithersburg, MARYLAND (USA)
Our recombinant nanoparticle vaccine technology combines the power and speed of genetic engineering to efficiently produce a new class of highly immunogenic particles that target a variety of viral pathogens. Our recombinant vaccine engineering takes a new approach to provide robust and functional immunity, which may be more efficacious than naturally occurring ...
Manufactured by:Novavax based inGaithersburg, MARYLAND (USA)
With the ongoing development of our NanoFlu™ and RSV F vaccines, a strong rationale exists for developing a combination respiratory vaccine that is designed to protect susceptible populations against both diseases. Although testing is at an early stage, we believe that a combination vaccine against both seasonal influenza and RSV may be ...
Manufactured by:Abera Bioscience AB based inUppsala, SWEDEN
Abera’s proprietary vaccine delivery platform – BERA, enables high-level multivalent presentation of recombinant antigens on bacterial Outer Membrane Vesicles (OMVs) for strong stimulation of the immune ...
Manufactured by:2A Pharma ApS based inAalborg Øst, DENMARK
2A Pharma’s B-cell epitope vaccine candidate, AAVLP-IgE, has in laboratory tests with non-human primates been shown to be effective at inducing anti-IgE autoantibodies. This gives the potential for a vaccine with similar benefits to approved anti-human immunoglobulin E (IgE) antibody treatments of, for example, asthma, nut allergy etc. Currently, the ...
Manufactured by:2A Pharma ApS based inAalborg Øst, DENMARK
2A Pharma’s anti-amyloid-beta vaccine candidate, AAVLP-Amyloid-β, has in laboratory tests with transgenic mice over-expressing amyloid-beta mutant protein been shown to eliminate amyloid-beta soluble protein, a clear plaque from the cortex and significantly reduce plaque from the hippocampus. ...
Manufactured by:Novavax based inGaithersburg, MARYLAND (USA)
Historically, we developed a vaccine candidate against MERS, a novel coronavirus first identified in 2012, as well as a vaccine candidate against SARS in 2005. In 2012, within weeks of obtaining the sequence of the circulating MERS strain, we successfully produced a vaccine candidate. Our MERS candidate was based on the major surface spike ...
Manufactured by:2A Pharma ApS based inAalborg Øst, DENMARK
2A Pharma’s AAVLP-HER2/Neu peptide vaccine candidate has in laboratory tests been shown to induce antibodies specific to human HER2. In mouse models, regression of breast cancer tumors was observed after vaccination. In a proof-of-principle study carried out at the Medical University of Vienna, Austria, supported by Medigene AG, it was concluded that this ...
Manufactured by:2A Pharma ApS based inAalborg Øst, DENMARK
Head and neck cancers represent the sixth most common cancer worldwide, resulting in more than 350,000 deaths/year. Our AAVLP-HNC vaccine uses our mimotope selection technology and has the potential to minimize side effects, improve efficacy, and markedly reduce treatment costs. This will address an unmet medical need and benefit cancer patients as well as reduce healthcare ...
Manufactured by:Novavax based inGaithersburg, MARYLAND (USA)
Historically, we developed a vaccine candidate against MERS, a novel coronavirus first identified in 2012, as well as a vaccine candidate against SARS in 2005. In 2012, within weeks of obtaining the sequence of the circulating MERS strain, we successfully produced a vaccine candidate. Our MERS candidate was based on the major surface spike ...